Avelumab and Merkel Cell Carcinoma: Biological Plausibility Explained
From General Health Education to Occupational Exposure Concerns
For decades, public health communication has centered on general wellness and the broad dissemination of scientific knowledge. This legacy heritage emphasized preventive behaviors and the understanding of disease processes at a population level, often focusing on lifestyle factors and environmental influences. Within this framework, the public has been educated about the importance of immune function and the body’s natural defenses against abnormal cell growth. As scientific inquiry advanced, attention gradually shifted toward specific pharmaceutical interventions and their long-term effects. In the context of mass production environments, where workers may be exposed to a variety of chemical and biological agents, the need for targeted occupational health surveillance becomes paramount. This transition from general health information to occupational exposure concern is particularly relevant when considering therapeutic agents like Avelumab, a monoclonal antibody used in oncology. While Avelumab is designed to enhance immune response against tumors, its administration in occupational settings—such as during manufacturing or handling—raises questions about potential unintended consequences. Specifically, the biological plausibility of Avelumab exposure influencing Merkel Cell Carcinoma risk warrants careful examination, moving the discussion from broad health education to a focused occupational safety consideration.
Bridging to Avelumab's Mechanism and Merkel Cell Carcinoma Etiology
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite this therapeutic benefit, the biological plausibility of avelumab causing or contributing to MCC must be examined separately from its intended antitumor activity. MCC has two primary etiologies: approximately 80% of cases are caused by the Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 pathway, thereby enhancing T-cell responses against tumors (https://pubmed.ncbi.nlm.nih.gov/34445385/).
Immune-Related Adverse Events and Theoretical Carcinogenic Pathways
Immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can involve various organs and may theoretically create an inflammatory microenvironment that could influence tumor development or progression. For instance, a case of hypercalcemia due to reactivation of sarcoidosis during avelumab treatment for metastatic MCC has been reported, indicating that avelumab can trigger granulomatous inflammation (https://pubmed.ncbi.nlm.nih.gov/31543781/). Such immune dysregulation could, in principle, contribute to the emergence of new malignancies, including MCC, though direct evidence linking avelumab to MCC causation is lacking. Mechanistic pathways that might link avelumab to MCC development are speculative. One possibility is that immune checkpoint inhibition could disrupt the balance between immune surveillance and tumor immune evasion. In MCC, down-regulation of MHC complexes and induction of anti-inflammatory cytokines are mechanisms by which tumors resist immune attack (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, by blocking PD-L1, might inadvertently select for tumor clones that are resistant to immune-mediated killing, potentially allowing for the outgrowth of MCC cells. However, this is a theoretical concern rather than an established causal pathway.
Risk Context: Approved Indication and Causation Considerations
Another consideration is that avelumab could unmask or accelerate the growth of pre-existing, subclinical MCC lesions by altering the immune microenvironment. This is analogous to the phenomenon of pseudoprogression seen with checkpoint inhibitors, where tumors initially appear to grow before responding. However, no published evidence directly demonstrates that avelumab causes de novo MCC. Regarding risk anchors, the adequacy of warnings about avelumab and MCC is informed by the drug's approved indication. Avelumab is specifically indicated for the treatment of metastatic MCC, meaning that its use is intended for patients who already have the disease (https://pubmed.ncbi.nlm.nih.gov/29799096/). Therefore, warnings about avelumab causing MCC would be counterintuitive, as the drug is used to treat MCC. However, for patients who develop MCC after avelumab exposure for another indication (e.g., other cancers), the question of causation arises. In such cases, the timeline between exposure and documented harm is critical. The JAVELIN Merkel 200 trial and subsequent studies have focused on avelumab's efficacy in MCC, not on its potential to induce the disease. For avelumab-refractory MCC, patients have been treated with combined ipilimumab and nivolumab, suggesting that avelumab does not universally prevent disease progression (https://pubmed.ncbi.nlm.nih.gov/33439294/). The median time to response or progression in these studies provides some temporal context, but no specific data on the latency period for avelumab-associated MCC development exist.
Summary of Biological Plausibility and Clinical Vigilance
Causation-related considerations for affected patients are complex. Given that avelumab is used to treat MCC, any new MCC diagnosis in a patient receiving avelumab for another condition would require careful evaluation of alternative etiologies, such as MCPyV infection or UV exposure. The biological plausibility of avelumab causing MCC is weak, as the drug's mechanism of action is to enhance antitumor immunity, not to induce oncogenesis. However, immune-related adverse events, including rare cases of secondary malignancies, have been reported with other checkpoint inhibitors, and avelumab's safety profile includes a range of irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781/). Without direct evidence from clinical trials or case reports linking avelumab to MCC causation, the risk appears low. Nonetheless, patients and clinicians should remain vigilant for any new skin lesions during avelumab therapy, and any suspicious findings should be biopsied to rule out MCC or other malignancies. In summary, while avelumab is an effective treatment for metastatic MCC, there is no established biological plausibility for avelumab causing MCC. The drug's mechanism of action, approved indication, and available safety data do not support a causal link. However, theoretical mechanisms involving immune dysregulation and tumor immune evasion warrant further investigation. For patients who develop MCC after avelumab exposure, the timeline and alternative risk factors should be carefully assessed.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can Avelumab cause Merkel Cell Carcinoma?
There is no established biological plausibility that Avelumab causes Merkel Cell Carcinoma (MCC). Avelumab is an immune checkpoint inhibitor used to treat metastatic MCC, and its mechanism of action enhances antitumor immunity rather than inducing oncogenesis. However, theoretical mechanisms involving immune dysregulation exist, but direct evidence is lacking.
What should I do if I develop a new skin lesion while on Avelumab?
Patients and clinicians should remain vigilant for any new skin lesions during Avelumab therapy. Any suspicious findings should be biopsied to rule out MCC or other malignancies, as immune-related adverse events can occur.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.